L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.06 NOK 0.8%
Market Cap: 345.4m NOK

Lytix Biopharma AS
Investor Relations

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

Show more
Loading

Earnings Calls

2024 Q4
Feb 13, 2025
Show Transcript
Previous
Next
Bolsa Mexicana de Valores Reports Strong Q4 2024 Results with Notable Growth
2024 Q4
Feb 13, 2025

In Q4 2024, Bolsa Mexicana de Valores showcased robust growth, with revenues slightly surpassing MXN 1.1 billion, an increase of 12%. This performance was fueled by heightened cross-border activity and a successful transition to new benchmark rates. EBITDA rose by 13%, reaching MXN 671 million, yielding a 59% margin, while net income saw a 14% increase to MXN 467 million. The company is optimistic about upcoming opportunities, including entering new markets and expanding their technology investments for growth. They aim for a dividend of MXN 2.05 per share, reflecting 70% of net income, while also expecting continued revenue enhancement in 2025.

Show Full Analysis

Management

Dr. Oystein Rekdal Ph.D.
Co-Founder & CEO
No Bio Available
Mr. Gjest Breistein M.Sc.
Chief Financial Officer
No Bio Available

Contacts

Address
OSLO
Oslo
Hoffsveien 4
Contacts